Emerging therapies for metabolic diseases--the focus is on diabetes and obesity.

Curr Opin Chem Biol

Zafgen, Inc., 5 Cambridge Center, Floor 2, Cambridge, MA 02142, United States.

Published: June 2009

Type 2 diabetes and obesity remain the focus of investigational drugs for metabolic disease. Only one new class of agents (Dipeptidylpeptidase 4 Inhibitors) has been approved in this field for control of blood glucose in patients with type 2 diabetes. Significant progress has been made in the elucidation of pathways of interest for new therapies in diabetes and obesity, partly through advances in human genetics that have highlighted genetic loci relevant to pancreatic beta cell dysfunction and hypothalamic control of food intake, respectively. Investigational drugs targeting these pathways are in early clinical investigation, including GPR119 agonists. Compounds targeting lipid partitioning and lipid biosynthetic enzymes also have emerged, including inhibitors of the enzymes DGAT1 and SCD1.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbpa.2009.04.622DOI Listing

Publication Analysis

Top Keywords

diabetes obesity
12
type diabetes
8
investigational drugs
8
emerging therapies
4
therapies metabolic
4
metabolic diseases--the
4
diseases--the focus
4
diabetes
4
focus diabetes
4
obesity type
4

Similar Publications

One hallmark of cancer is the upregulation and dependency on glucose metabolism to fuel macromolecule biosynthesis and rapid proliferation. Despite significant pre-clinical effort to exploit this pathway, additional mechanistic insights are necessary to prioritize the diversity of metabolic adaptations upon acute loss of glucose metabolism. Here, we investigated a potent small molecule inhibitor to Class I glucose transporters, KL-11743, using glycolytic leukemia cell lines and patient-based model systems.

View Article and Find Full Text PDF

Background: Classic congenital adrenal hyperplasia, primarily due to 21-hydroxylase deficiency, leads to impaired cortisol and aldosterone production and excess adrenal androgens. Lifelong glucocorticoid therapy is required, often necessitating supraphysiological doses in youth to manage androgen excess and growth acceleration. These patients experience higher obesity rates, hypertension, and glucose metabolism issues, complicating long-term health management.

View Article and Find Full Text PDF

Maternal and neonatal outcomes after metabolic and bariatric surgery among women with severe obesity.

Surg Obes Relat Dis

January 2025

Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York; Division of Health Services Policy and Practice, Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York.

Background: Earlier evidence indicated that metabolic and bariatric surgery (MBS) may adversely affect neonatal outcomes among patients conceiving soon after MBS, but recent studies demonstrated conflicting results, especially for new surgical techniques.

Objectives: The aim of this study was to assess the effects of MBS types and surgery to birth interval on maternal, birth, and nonbirth outcomes in women with severe obesity.

Setting: New York State's all-payer hospital discharge database (2008-2019).

View Article and Find Full Text PDF

Introduction: The global prevalence of people living with overweight has tripled since 1975 and more than 40% of Danish women enter pregnancy being overweight. With the increasing rates of obesity observed in children, adolescents and adults, there is an urgent need for preventive measures. Risk factors for childhood obesity include maternal overweight or obesity before conception and excessive weight gain during pregnancy.

View Article and Find Full Text PDF

Cardiovascular disease (CVD) is a major driver of mortality and declining health worldwide. Cardiovascular diseases (CVD) is the most common cause of morbidity and mortality globally. Although dyslipidemia, smoking, diabetes, hypertension and obesity are some well-known causes of CVD, the overlapping genetic pathways between other diseases and those affecting cardiovascular health have been overlooked.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!